Multifunctional Tandem Peptide Mediates Targeted siRNA Delivery to Ovarian Cancer Cells
- 4 June 2025
- journal article
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 8 (6) , 4612-4620
Abstract
Fusogenic peptides have been developed to enhance the delivery efficiency of nucleic acids such as small interfering RNAs (siRNAs). Fusogenic peptides can protect nucleic acids from degradation and facilitate endosomal escape, but their systemic delivery capabilities remain unrefined. Active targeting of delivery systems to overexpressed cell receptors can be used to enhance cell- and tissue-specific delivery of therapeutic payloads while reducing off-target and systemic effects. We aimed to develop a targeted fusogenic (tandem) peptide, LHRHR-DIV3W, capable of targeting the luteinizing hormone-releasing hormone receptor (LHRHR), which is overexpressed in ovarian cancer cells and tissues. Characterization studies revealed that our tandem peptide, LHRHR-DIV3W, formed monodisperse nanocomplexes that protected siRNAs in physiological environments. We also demonstrated receptor-specific internalization of peptide-siRNA nanocomplexes in ovarian cancer cell lines with upregulated LHRHR expression. Furthermore, we observed that the inclusion of both the fusogenic DIV3W sequence and the LHRHR-targeting sequences in the tandem peptide enhanced receptor-specific siRNA internalization in ovarian cancer cells by up to 40% compared with the LHRHR-targeting peptide alone, indicating the necessity of combining both peptide regions. Finally, we demonstrated significant silencing of CSNK2A1, an oncogene overexpressed in ovarian cancer, in the ovarian cancer cell line OVCAR3. Our findings establish the use of a tandem peptide with cell-targeting and membrane-disruptive abilities as a delivery platform for nucleic acid therapies.Keywords
Funding Information
- Hollings Cancer Center, Medical University of South Carolina
- Office of Integrative Activities (1655740)
- National Institute of General Medical Sciences (P30 GM131959)
- Clemson University
- Division of Materials Research (2046694)
This publication has 45 references indexed in Scilit:
- Therapeutic siRNA: State-of-the-Art and Future PerspectivesBioDrugs, 2022
- Ovarian cancer: Current status and strategies for improving therapeutic outcomesCancer Medicine, 2019
- Functional peptides for siRNA deliveryAdvanced Drug Delivery Reviews, 2017
- CK2α phosphorylates DBC1 and is involved in the progression of gastric carcinoma and predicts poor survival of gastric carcinoma patientsInternational Journal of Cancer, 2014
- Fusion protein linkers: Property, design and functionalityAdvanced Drug Delivery Reviews, 2013
- Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advancesAdvanced Drug Delivery Reviews, 2013
- Targeted chemotherapy of endometrial, ovarian and breast cancers with cytotoxic analogs of luteinizing hormone-releasing hormone (LHRH)Archives of Gynecology and Obstetrics, 2012
- Therapeutic cancer targeting peptidesPeptide Science, 2002
- Orientation into the lipid bilayer of an asymmetric amphipathic helical peptide located at the N-terminus of viral fusion proteinsBiochimica et Biophysica Acta (BBA) - Biomembranes, 1990
- Receptor-mediated internalization of LHRH antagonists by pituitary cellsMolecular and Cellular Endocrinology, 1983